FACULTY

UMBERTO RESTELLI ha conseguito un Dottorato di Ricerca in Gestione Integrata d’Azienda presso l’Università Cattaneo – LIUC. È docente a contratto del corso “Modelli di funzionamento dei sistemi sanitari”.

È “honorary senior lecturer” presso la School of Public Health, Faculty of Health Sciences della Witwatersrand University di Johannesburg.

I suoi principali interessi di ricerca includono l’Economia Sanitaria, l’Health Technology Assessment e il Management Sanitario. Nel dettaglio, la valutazione dell’impatto delle tecnologie sanitarie a livello meso e macro (adattamento di modelli di costo-efficacia e costo-utilità, implementazione di modelli di valutazione di impatto sul budget, valutazione dell’impatto organizzativo, analisi di costo-beneficio).

Ha collaborato e/o coordinato più di 50 progetti di ricerca per committenti quali: la Commissione Europea; l’Organizzazione Mondiale della Sanità; il Ministero dell’Istruzione, dell’Università e della Ricerca; il Ministero della Salute; il Ministero degli Affari Esteri; strutture ospedaliere, aziende sanitarie locali, aziende farmaceutiche.

Restelli U, Saibene G, Nardulli P et al. Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open. 2017 Aug 1;7(7):e015645.

2. Restelli U, Rizzardini G, Antinori A et al. Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients. Ther Clin Risk Manag. 2017;13:787-797.

3. Restelli U, Di Giambenedetto S, Fabbiani M et al. Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the ATLAS-M Trial. Clinicoecon Outcomes Res. 2017;9:173-179.

4. Restelli U, Alberti A, Lazzarin A et al. Cost effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) Vs. sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of Hepatitis C Virus genotype 3 infected patients in Italy. Eur J Health Econ. 2016 Dec 22. Epub ahead of print

5. Creazza A, Restelli U, Porazzi E et al. Benchmarking of Health Technologies distribution models: an investigation of Lombardy’s Local Health Authorities. Benchmarking, an International Journal 2016;23(4):817-842.

6. Croce D, Bonfanti M, Restelli U. Financial and feasibility implications of the treatment of Hepatitis C Virus in Italy: scenarios and perspectives. Clinicoecon Outcomes Res. 2016 Aug 8;8:377-85.

7. Restelli U, Croce D, Rizzardini G. Antiretroviral treatments’ durability and costs: important elements in the choice of first line therapy. AIDS. 2016 Sep 10;30(14):2247-9.

8. Restelli U, Faggioli P, Scolari F et al. Organizational impact of the introduction of a new portable syringe pump for Iloprost therapy in Italian hospital settings. Current Drug Therapy 2015;10(2):105-112.

9. Restelli U, Scolari F, Bonfanti P et al. New Highly Active Antiretroviral drugs and generic drugs for the treatment of HIV infection: a budget impact analysis on the Italian National Health Service (Lombardy Region, Northern Italy). BMC Infect Dis. 2015 Aug 11;15(1):323.

10. Restelli U, Andreoni M, Antinori A et al. Budget impact analysis of antiretroviral less drug regimen simplification in HIV-positive patients on the Italian National Health Service. Clinicoecon Outcomes Res. 2014 Sep 23;6:409-14.